LCTX compared with IMDX: revenue, margins and what each company keeps, and the suppliers and customers both name

LCTXLineage Cell Therapeutics, Inc.

Mkt capRevenueRevenue

IMDXInsight Molecular Diagnostics Inc.

Mkt capRevenueRevenue

Compare

LCTXLineage Cell Therapeutics, Inc.

IMDXInsight Molecular Diagnostics Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LCTX1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−2.65%—

IMDX1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±70.8%▼−7.13%×0.10

= impliedLCTX realized, solidIMDX realized, hatchedOne scale, both sides: full bar = 71%× = |realized| ÷ impliedSource: market data

LCTXLineage Cell Therapeutics, Inc.

1.01▼−2.30%· post 1.01

Mkt cap$252.9MRevenue$1MQ2 FY26Revenue$15MFY25

IMDXInsight Molecular Diagnostics Inc.

2.97▼−6.51%· post 2.97

ClosedOct 30 '26

Mkt cap$96.9MRevenue$239,000Q2 FY26Revenue$4MFY25

Compare

ClosedOct 30 '26

LCTXLineage Cell Therapeutics, Inc.

IMDXInsight Molecular Diagnostics Inc.

1.01▼−2.30%post 1.01

Price

2.97▼−6.51%post 2.97

$252.9M

Mkt cap

$96.9M

Q2 FY26$1M

Revenue

$239,000Q2 FY26

FY25$15M

Revenue

$4MFY25

LCTX1.01▼−2.30%vsIMDX2.97▼−6.51%ClosedOct 30 '26